Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of fezolinetant in Chinese women with menopausal hot flashes (Moonlight 3)
NCT04451226Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fezolinetant in hot flashes, sponsored by Astellas Pharma. Started Jul 2020; status: completed.
02
Drugs
fezolinetant
03
Conditions
hot flashes
Beyond the preview
Go deeper on NCT04451226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04451226.